[go: up one dir, main page]

AR062536A1 - Acilanilidas sustituidas y composicion farmaceutica - Google Patents

Acilanilidas sustituidas y composicion farmaceutica

Info

Publication number
AR062536A1
AR062536A1 ARP070103786A ARP070103786A AR062536A1 AR 062536 A1 AR062536 A1 AR 062536A1 AR P070103786 A ARP070103786 A AR P070103786A AR P070103786 A ARP070103786 A AR P070103786A AR 062536 A1 AR062536 A1 AR 062536A1
Authority
AR
Argentina
Prior art keywords
acilanilids
substituted
pharmaceutical composition
disease
disorder
Prior art date
Application number
ARP070103786A
Other languages
English (en)
Original Assignee
Univ Tennesee Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/510,844 external-priority patent/US20070066568A1/en
Application filed by Univ Tennesee Res Foundation filed Critical Univ Tennesee Res Foundation
Publication of AR062536A1 publication Critical patent/AR062536A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C07C255/51—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings containing at least two cyano groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Estos compuestos son utiles en el tratamiento de una variedad de enfermedades o afecciones en un sujeto, que incluyen, entre otras, una enfermedad y/o trastorno de desgaste muscular o una enfermedad y/o trastorno relacionado con los huesos. Reivindicacion 1: Un compuesto representado por la estructura de formula (1): o su isomero, sal farmacéuticamente aceptable, producto farmacéutico, polimorfo, cristal, N-oxido, hidrato o cualquier combinacion de ellos.
ARP070103786A 2006-08-24 2007-08-27 Acilanilidas sustituidas y composicion farmaceutica AR062536A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83966506P 2006-08-24 2006-08-24
US11/510,844 US20070066568A1 (en) 2005-08-31 2006-08-28 Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
PCT/US2006/033490 WO2007027582A2 (en) 2005-08-31 2006-08-28 Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US90774907P 2007-04-16 2007-04-16

Publications (1)

Publication Number Publication Date
AR062536A1 true AR062536A1 (es) 2008-11-12

Family

ID=48170081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103786A AR062536A1 (es) 2006-08-24 2007-08-27 Acilanilidas sustituidas y composicion farmaceutica

Country Status (19)

Country Link
US (3) US8080682B2 (es)
EP (2) EP3056483A1 (es)
JP (2) JP5345534B2 (es)
KR (2) KR101202240B1 (es)
CN (3) CN101528214B (es)
AR (1) AR062536A1 (es)
AU (1) AU2007287070C1 (es)
BR (1) BRPI0714526A2 (es)
CA (1) CA2660570C (es)
CY (1) CY1117817T1 (es)
DK (1) DK2054049T3 (es)
EA (1) EA016853B1 (es)
ES (1) ES2581765T3 (es)
HU (1) HUE029808T2 (es)
IL (3) IL197185A (es)
MX (1) MX2009001962A (es)
PL (1) PL2054049T3 (es)
PT (1) PT2054049E (es)
WO (1) WO2008024456A2 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445534B2 (en) * 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
EP1931199A4 (en) * 2005-08-31 2009-07-29 Univ Tennessee Res Foundation COMBATING NURSE DISEASE, BURNS, WOUNDS AND BACKMARK INJURIES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) * 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
PT2054049E (pt) 2006-08-24 2016-06-02 Univ Tennessee Res Found Acilanilidas substituídas e métodos de utilização das mesmas
US10010521B2 (en) * 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
SI2915529T1 (sl) 2008-05-07 2017-09-29 The Regents Of The University Of California Terapevtska regeneracija in obogatitev lubrikacije okularne površine
WO2010027743A1 (en) * 2008-08-25 2010-03-11 Alpha Synergy Development, Inc. Pharmaceutical compositions and methods for the treatment of dry eye
WO2010056979A1 (en) * 2008-11-14 2010-05-20 Immune Control, Inc. Phenothiazine derivatives for treatment of asthma
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
ES2689700T3 (es) 2008-12-09 2018-11-15 Metabolic Technologies, Inc. Intervención nutricional para mejorar la función y resistencia muscular
US8870876B2 (en) * 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US20120149780A1 (en) * 2009-03-12 2012-06-14 Dilip S Mehta Method of Use of Vitamin K as Energy Enhancer in Diverse Disease States
US8277459B2 (en) * 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
CA2776950C (en) 2009-10-09 2023-11-21 Nestec S.A. Use of isoflavones in the prevention or treatment of sarcopenia and muscle atrophy
US8791158B2 (en) * 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
AU2015200324C1 (en) * 2010-03-23 2016-12-15 University Of Tennessee Research Foundation SARMs and method of use thereof
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
KR101875705B1 (ko) * 2011-12-07 2018-07-06 삼성전자주식회사 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물
KR20130063962A (ko) * 2011-12-07 2013-06-17 가천대학교 산학협력단 디아미노디페닐술폰을 포함하는 골량 저하 질환의 예방 또는 치료용 약학적 조성물
EP2822556A1 (en) * 2012-03-07 2015-01-14 Ligand Pharmaceuticals Inc. Steroid hormone and cholesterol pathways as one unified homestatic system
PT2846845T (pt) * 2012-05-09 2017-06-02 Icrom Spa Produção de brinzolamida farmacêutica estéril
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
IN2015DN01046A (es) 2012-07-13 2015-06-26 Gtx Inc
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP2893343B1 (en) 2012-09-07 2019-11-20 The Governors of the University of Alberta Methods for diagnosis of inflammatory liver disease
WO2014144907A1 (en) * 2013-03-15 2014-09-18 Children's Medical Center Corporation Methods and compounds for the treatment of dystroglycanopathies
KR20160067225A (ko) * 2013-10-24 2016-06-13 유니버시티 오브 테네시 리서치 파운데이션 암 환자에서 근육 소모를 치료하는 선택적 안드로겐 수용체 조절물질 및 화학치료제
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3288383A4 (en) 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
US10758504B2 (en) 2015-09-16 2020-09-01 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
CN110099688A (zh) * 2016-11-17 2019-08-06 赛途公司 骨骼肌肥大诱导物
CN106748884B (zh) * 2016-12-13 2021-08-20 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
JP7207308B2 (ja) * 2017-08-03 2023-01-18 ソニーグループ株式会社 コンタクトレンズおよび検出方法
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
CN109207724B (zh) * 2018-09-12 2020-12-29 哈尔滨工业大学（威海） 一种从含钒铬溶液中同时萃取分离钒铬的萃取溶剂及萃取方法
CN109761778A (zh) * 2018-12-10 2019-05-17 石家庄市度智医药科技有限公司 一种合成光学活性α-羟基丙酰胺衍生物的方法
CN111418558B (zh) * 2019-09-22 2021-09-28 山西大学 一种消融代谢性泌尿结石动物模型的构建方法
JP2023511612A (ja) * 2020-01-27 2023-03-20 エイルゲン ファーマ リミテッド 腎臓疾患の治療のためのテトラヒドロシクロペンタ［ｂ］インドール化合物
CA3149708A1 (en) 2020-02-10 2021-02-08 Virox Technologies Inc. Antimicrobial compositions containing peroxyphthalic acid and/or salt thereof
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
US20250281486A1 (en) * 2022-05-05 2025-09-11 The Trustees Of Indiana University Therapeutic strategies to manage facial contractures post injury
CN114796496B (zh) * 2022-05-09 2023-06-23 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 交感神经活化抑制剂和/或α1-肾上腺素能受体抑制剂在制备治疗干眼症的药物中的应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256096A (en) 1961-08-11 1966-06-14 Organic Nutrients Inc Anabolic stimulator as a poultry feed supplement
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US3949085A (en) 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US3865801A (en) 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US3946109A (en) 1973-08-08 1976-03-23 Ernst Kolb Animal feed composition containing certain vitamin combinations
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US4211781A (en) 1974-09-23 1980-07-08 Pfizer Inc. Process for the preparation of dustless quinoxaline-1,4-dioxide animal feed supplement premixes
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
US4447421A (en) 1980-05-08 1984-05-08 American Cyanamid Company Process for the preparation of medicated animal feed supplement
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
US4670249A (en) 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
US4837004A (en) 1985-10-18 1989-06-06 Eastman Kodak Company Rumen-stable pellets
US4904473A (en) 1986-06-23 1990-02-27 International Minerals & Chemical Corp. Ruminant feed antacid containing potassium, sodium and chlorine
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US4849447A (en) 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
JPH03502326A (ja) 1988-01-28 1991-05-30 ポリゲン　ホールディング　コーポレイション 成長ホルモン放出活性を有するポリペプチド化合物類
ATE122357T1 (de) 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
US4977288A (en) 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
US5030657A (en) 1989-10-23 1991-07-09 University Of Georgia Research Foundation, Inc. L-carnitine supplemented catfish diet
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
WO1995019770A1 (en) 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
CA2149496C (en) 1994-05-19 2006-12-19 Ronald Gebhard 11,21-bisphenyl-19-norpregnane derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998053826A1 (en) 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en) 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
US6022137A (en) 1998-04-29 2000-02-08 Buckeye Feed Mills, Inc. Conditioner for processing raw grain composition to produce pelletized feed
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
SI1169312T1 (en) 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
WO2001027622A1 (en) 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
NZ518392A (en) 1999-10-19 2004-02-27 Nobex Corp Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
BR0015124A (pt) 1999-10-27 2002-07-02 Nobex Corp Método de preparação de um enanciÈmero substancialmente puro
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU2625201A (en) 2000-01-03 2001-07-16 Ramot University Authority For Applied Research And Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US6441197B1 (en) * 2000-01-20 2002-08-27 Daiichi Pure Chemicals Co., Ltd. Diaminofluorescein derivative
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
AU8821301A (en) 2000-06-28 2002-01-08 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, design and use
JP2002035743A (ja) * 2000-07-21 2002-02-05 Kurita Water Ind Ltd 軟水装置
AU2001285230C1 (en) 2000-08-24 2008-03-13 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
IL162340A0 (en) * 2001-12-06 2005-11-20 Gtx Inc Treating muscle wasting with selective androgen receptor modulators
DE60317631T2 (de) 2002-02-01 2008-09-25 Merck & Co., Inc. 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie
DK1480634T3 (da) 2002-02-07 2011-11-14 Univ Tennessee Res Foundation Selektive androgenreceptormodulatorer (SARM) til behandling af benign prostatahyperplasi
ATE533494T1 (de) * 2002-02-28 2011-12-15 Univ Tennessee Res Foundation Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür
WO2003074450A2 (en) 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US20040147489A1 (en) 2002-02-28 2004-07-29 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
CA2512049A1 (en) 2002-12-30 2004-07-22 Purdue Research Foundation Method of treatment for central nervous system injury
CA2514024A1 (en) * 2003-01-22 2004-08-05 Gtx Inc. Treating androgen deficiency in female (adif)-associated conditions with sarms
GB0308335D0 (en) 2003-04-10 2003-05-14 Novartis Ag Organic compounds
CA2534314C (en) 2003-09-12 2012-11-13 Applied Research Systems Ars Holding N.V. Benzothiazole derivatives for the treatment of diabetes
MXPA06002462A (es) * 2003-10-14 2006-06-20 Gtx Inc Tratamiento de desordenes relacionados con huesos con moduladores del receptor de angrogeno selectivo.
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
ES2329489T3 (es) 2004-05-03 2009-11-26 F. Hoffmann-La Roche Ag Derivados de indolilo como moduladores del receptor x del higado.
CA2543827C (en) * 2004-06-07 2010-03-09 James T. Dalton Selective androgen receptor modulators and methods of use thereof
AU2005275279A1 (en) 2004-07-14 2006-02-23 Janssen Pharmaceutica N.V. Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
WO2006011141A2 (en) 2004-07-25 2006-02-02 Israel Aerospace Industries Ltd. Method and system for the acquisition of data and for the display of data
EP1931199A4 (en) * 2005-08-31 2009-07-29 Univ Tennessee Res Foundation COMBATING NURSE DISEASE, BURNS, WOUNDS AND BACKMARK INJURIES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
CA2628259A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
JP2009513704A (ja) 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ジヒドロイソインドロン
WO2007075702A2 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
PT2054049E (pt) 2006-08-24 2016-06-02 Univ Tennessee Res Found Acilanilidas substituídas e métodos de utilização das mesmas
US8791158B2 (en) * 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction

Also Published As

Publication number Publication date
CN103251579B (zh) 2016-12-28
IL230759A0 (en) 2014-03-31
CA2660570A1 (en) 2008-02-28
IL230759A (en) 2016-03-31
JP5345534B2 (ja) 2013-11-20
IL197185A (en) 2014-02-27
AU2007287070A1 (en) 2008-02-28
HUE029808T2 (en) 2017-03-28
US8426465B2 (en) 2013-04-23
WO2008024456A2 (en) 2008-02-28
MX2009001962A (es) 2009-04-30
IL244442A0 (en) 2016-04-21
EP2054049B1 (en) 2016-04-13
KR101264820B1 (ko) 2013-05-22
PT2054049E (pt) 2016-06-02
PL2054049T3 (pl) 2016-11-30
EP2054049A2 (en) 2009-05-06
CN103251579A (zh) 2013-08-21
US8080682B2 (en) 2011-12-20
US8846756B2 (en) 2014-09-30
CN107007581A (zh) 2017-08-04
AU2007287070B2 (en) 2012-07-05
KR20110081906A (ko) 2011-07-14
ES2581765T3 (es) 2016-09-07
IL197185A0 (en) 2009-12-24
US20080076829A1 (en) 2008-03-27
EP2054049A4 (en) 2010-12-29
JP5745560B2 (ja) 2015-07-08
EA200900345A1 (ru) 2009-08-28
CN101528214A (zh) 2009-09-09
CN101528214B (zh) 2013-06-05
CA2660570C (en) 2016-08-09
CY1117817T1 (el) 2017-05-17
KR101202240B1 (ko) 2012-11-16
JP2013139472A (ja) 2013-07-18
AU2007287070C1 (en) 2013-02-14
WO2008024456A3 (en) 2008-07-03
BRPI0714526A2 (pt) 2013-04-30
JP2010501574A (ja) 2010-01-21
IL244442B (en) 2018-05-31
US20130324602A1 (en) 2013-12-05
KR20090061010A (ko) 2009-06-15
EP3056483A1 (en) 2016-08-17
EA016853B1 (ru) 2012-08-30
US20120136052A1 (en) 2012-05-31
DK2054049T3 (en) 2016-08-01

Similar Documents

Publication Publication Date Title
AR062536A1 (es) Acilanilidas sustituidas y composicion farmaceutica
AR061980A1 (es) Acilanilidas sustituidas y metodos para su utilizacion
UY28955A1 (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
ECSP10010335A (es) Pirrolo-pirimidinas y pirrolo-piridinas
AR060675A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos.
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
SG135192A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
EA200601584A1 (ru) Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
AR062111A1 (es) Derivados de beta-d-glucopiranosil indol, metodo de preparacion, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
MX2023014630A (es) Activadores de dimetoxifenilalquilamina de receptores de serotonina.
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
CY1118179T1 (el) Φαρμακευτικη συνθεση
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
ATE528306T1 (de) Benzoxazepin-verbindungen, ihre herstellung und verwendung
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
GT200500281A (es) Compuestos organicos.
GT200600160A (es) Tratamiento del dolor

Legal Events

Date Code Title Description
FG Grant, registration